PDF(Sci-hub)
Abstract：
BACKGROUND: Deregulation of the RNA polymerase III specific TFIIIB subunit BRF2 occurs in subtypes of human cancers. However, correlations between BRF2 alterations and clinical outcomes in breast cancer are limited. We conducted this review to analyze BRF2 alterations in genomic data sets housed in Oncomine and cBioPortal to identify potential correlations between BRF2 alterations and clinical outcomes.
METHODS: The authors queried both Oncomine and cBioPortal for alterations in BRF2 in human cancers and performed meta-analyses identifying significant correlations between BRF2 and clinical outcomes in invasive breast cancer (IBC).
RESULTS: A meta cancer outlier profile analysis (COPA) of 715 data sets (86,733 samples) in Oncomine identified BRF2 as overexpressed in 60% of breast cancer data sets. COPA scores in IBC data sets (3594 patients) are comparable for HER2 (24.211, median gene rank 60) and BRF2 (29.656, median gene rank 36.5). Overall survival in IBC patients with BRF2 alterations (21%) is significantly decreased (p = 9.332e-3). IBC patients with BRF2 alterations aged 46 to 50 have a significantly poor survival outcome (p = 7.093e-3). Strikingly, in metastatic breast cancer, BRF2 is altered in 33% of women aged 45-50. BRF2 deletions are predominant in this age group.
CONCLUSIONS: This study suggests BRF2 may be an prognostic biomarker in invasive breast carcinoma.
METHODS: The authors queried both Oncomine and cBioPortal for alterations in BRF2 in human cancers and performed meta-analyses identifying significant correlations between BRF2 and clinical outcomes in invasive breast cancer (IBC).
RESULTS: A meta cancer outlier profile analysis (COPA) of 715 data sets (86,733 samples) in Oncomine identified BRF2 as overexpressed in 60% of breast cancer data sets. COPA scores in IBC data sets (3594 patients) are comparable for HER2 (24.211, median gene rank 60) and BRF2 (29.656, median gene rank 36.5). Overall survival in IBC patients with BRF2 alterations (21%) is significantly decreased (p = 9.332e-3). IBC patients with BRF2 alterations aged 46 to 50 have a significantly poor survival outcome (p = 7.093e-3). Strikingly, in metastatic breast cancer, BRF2 is altered in 33% of women aged 45-50. BRF2 deletions are predominant in this age group.
CONCLUSIONS: This study suggests BRF2 may be an prognostic biomarker in invasive breast carcinoma.
摘要：
背景：RNA聚合酶III特异性TFIIIB亚基BRF2的失调发生在人类癌症的亚型中。然而,BRF2改变与乳腺癌临床结局之间的相关性有限.我们进行了这篇综述，以分析Oncomine和cBioPortal中基因组数据集中的BRF2改变，以确定BRF2改变与临床结果之间的潜在相关性。
方法：作者查询了Oncomine和cBioPortal在人类癌症中BRF2的改变，并进行了荟萃分析，确定了BRF2与浸润性乳腺癌（IBC）临床结果之间的显着相关性。
结果：对Oncomine的715个数据集（86,733个样本）进行的meta癌症离群值分析（COPA）确定BRF2在60％的乳腺癌数据集中过表达。IBC数据集（3594名患者）中的COPA评分对于HER2（24.211，中位基因等级60）和BRF2（29.656，中位基因等级36.5）具有可比性。具有BRF2改变(21%)的IBC患者的总生存期显著降低(p=9.332e-3)。46至50岁的具有BRF2改变的IBC患者的生存结果明显较差（p=7.093e-3）。引人注目的是，在转移性乳腺癌中，33％的45-50岁女性发生BRF2改变。BRF2缺失在该年龄组中占主导地位。
结论：本研究提示BRF2可能是浸润性乳腺癌的预后生物标志物。
方法：作者查询了Oncomine和cBioPortal在人类癌症中BRF2的改变，并进行了荟萃分析，确定了BRF2与浸润性乳腺癌（IBC）临床结果之间的显着相关性。
结果：对Oncomine的715个数据集（86,733个样本）进行的meta癌症离群值分析（COPA）确定BRF2在60％的乳腺癌数据集中过表达。IBC数据集（3594名患者）中的COPA评分对于HER2（24.211，中位基因等级60）和BRF2（29.656，中位基因等级36.5）具有可比性。具有BRF2改变(21%)的IBC患者的总生存期显著降低(p=9.332e-3)。46至50岁的具有BRF2改变的IBC患者的生存结果明显较差（p=7.093e-3）。引人注目的是，在转移性乳腺癌中，33％的45-50岁女性发生BRF2改变。BRF2缺失在该年龄组中占主导地位。
结论：本研究提示BRF2可能是浸润性乳腺癌的预后生物标志物。
